CBS 2019
CBSMD教育中心
中 文

急性冠脉综合征

Abstract

Recommended Article

Optimal Timing of Intervention in NSTE-ACS Without Pre-Treatment The EARLY Randomized Trial Another Nail in the Coffin for Intra-Aortic Balloon Counterpulsion in Acute Myocardial Infarction With Cardiogenic Shock Effects of clopidogrel vs. prasugrel vs. ticagrelor on endothelial function, inflammatory parameters, and platelet function in patients with acute coronary syndrome undergoing coronary artery stenting: a randomized, blinded, parallel study Refractory Angina: From Pathophysiology to New Therapeutic Nonpharmacological Technologies Clinical Efficacy and Safety of Alirocumab after Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes Application of High-Sensitivity Troponin in Suspected Myocardial Infarction Incidence, predictors, and outcomes of DAPT disruption due to non-compliance vs. bleeding after PCI: insights from the PARIS Registry

Clinical Trial26 Sep 2019

JOURNAL:Circulation. Article Link

Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or with Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights from the AUGUSTUS Trial

S Windecker , RD Lopes, AUGUSTUS Investigators et al. Keywords: antithrombotic therapy; atrial fibrillation; ACS patients; safety and efficacy

FULL TEXT PDF